Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
FDA Approvals, News & Updates
FDA Approvals, News & Updates
FDA Approved Abecma, First CAR T-Cell Therapy for Multiple Myeloma
FDA Approvals, News & Updates
April 2021, Vol 12, No 2
On
March 27, 2021
, the FDA approved idecabtagene vicleucel (Abecma; Bristol Myers Squibb/Bluebird Bio), a B-cell maturation antigen (BCMA)-directed, genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with multiple myeloma whose disease did not respond to, or recurred, after ≥4 lines of therapy. Idecabtagene vicleucel is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. The FDA granted this indication orphan drug and breakthrough therapy designations.
Read Article
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
FDA Approvals, News & Updates
April 2021, Vol 12, No 2
On
February 9, 2021
, the FDA approved a new indication for cemiplimab-rwlc (Libtayo; Regeneron/sanofi-aventis) for the treatment of locally advanced or metastatic basal-cell carcinoma (BCC) in patients who had received or are ineligible to receive a hedgehog inhibitor. The FDA granted cemiplimab a priority review and accelerated its approval for this indication.
Read Article
Lorbrena Receives FDA Approval for First-Line Treatment of Metastatic Lung Cancer
FDA Approvals, News & Updates
April 2021, Vol 12, No 2
On
March 3, 2021
, the FDA approved a new indication for lorlatinib (Lorbrena; Pfizer), a third-generation
ALK
inhibitor, for the first-line treatment of patients with non–small-cell lung cancer (NSCLC) and
ALK
mutation.
Read Article
Yescarta First CAR T-Cell Therapy FDA Approved for Follicular Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
April 2021, Vol 12, No 2
On
March 5, 2021
, the FDA approved a new indication for axicabtagene ciloleucel (Yescarta; Kite Pharma), a chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received ≥2 lines of systemic therapy. The FDA granted this indication a priority review as well as breakthrough therapy and orphan drug designations.
Read Article
Vyxeos Now Indicated for Treatment of Pediatric Patients with AML
FDA Approvals, News & Updates
,
Leukemia
April 2021, Vol 12, No 2
On
March 30, 2021
, the FDA approved a new indication for daunorubicin and cytarabine (Vyxeos; Jazz Pharmaceuticals) for the treatment of pediatric patients aged ≥1 years with newly diagnosed, therapy-related acute myeloid leukemia (AML) or patients with AML and myelodysplasia-related changes. Daunorubicin and cytarabine is a liposomal combination of an anthracycline topoisomerase inhibitor (daunorubicin) and a nucleoside metabolic inhibitor (cytarabine).
Read Article
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone Lymphoma and Follicular Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
April 2021, Vol 12, No 2
On
February 5, 2021
, the FDA approved umbralisib (Ukoniq; TG Therapeutics), an oral kinase inhibitor, for the treatment of adults with relapsed or refractory marginal-zone lymphoma (MZL) or with relapsed or refractory follicular lymphoma (FL). Umbralisib is indicated for MZL after ≥1 CD20-directed regimens, and for FL after ≥3 lines of systemic therapy.
Read Article
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
April 2021, Vol 12, No 2
On
February 5, 2021
, the FDA approved lisocabtagene maraleucel (Breyanzi; Juno Therapeutics), a new CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after ≥2 previous lines of systemic therapy. The FDA granted lisocabtagene maraleucel priority review, as well as breakthrough therapy, orphan drug, and regenerative medicine advanced therapy designations.
Read Article
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
FDA Approvals, News & Updates
April 2021, Vol 12, No 2
On
February 12, 2021
, the FDA approved trilaciclib (Cosela; G1 Therapeutics), as a first-in-class cyclin-dependent kinase (CDK)4/6 inhibitor to reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer, when used before a platinum plus etoposide regimen or a topotecan-containing regimen. Trilaciclib may prevent damage to bone marrow cells by inhibiting the CDK4/6 enzyme. The FDA granted trilaciclib priority review and a breakthrough therapy designation.
Read Article
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
April 2021, Vol 12, No 2
On
February 26, 2021
, the FDA accelerated the approval of melphalan flufenamide (Pepaxto; Oncopeptides AB), an alkylating drug, for the treatment, in combination with dexamethasone, of adults with relapsed or refractory multiple myeloma who have received ≥4 lines of therapy and whose disease is triple-refractory to ≥1 proteasome inhibitors, 1 immunomodulatory drug, and 1 CD-38–directed monoclonal antibody.
Read Article
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & Updates
,
Multiple Myeloma
February 2021, Vol 12, No 1
On
December 18, 2020
, the FDA approved selinexor (Xpovio; Karyopharm Therapeutics) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adults with multiple myeloma after ≥1 previous therapies. The FDA granted this indication an orphan drug designation.
Read Article
Page 9 of 37
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma